4-(3-溴丙基)吗啉氢溴酸 | 88806-06-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 4-(3-溴丙基)吗啉氢溴酸
• 中文别名: 4-(3-溴丙基)吗啉氢溴酸盐
• 英文名称: 4-(3-Bromopropyl)morpholine hydrobromide
• 英文别名: 4-(3-bromopropyl)morpholine;hydrobromide
• CAS: 88806-06-8
• 化学式: C7H15Br2NO
• mdl: MFCD13176498
• 分子量: 289.01
• InChiKey: BOKDFWMGFIWGSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.88
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(1H-indazol-3-yl)isoindoline-1,3-dione 、 4-(3-溴丙基)吗啉氢溴酸 、 3-phthalimido-4-chloroindazole 、 3-溴-N,N-二乙基丙氨氢溴酸盐 以As a result, 8.7 g of 1-(3-morpholinopropyl)-3-(3-diethylaminopropylamino)indazole was obtained的产率得到1-(3-morpholinopropyl)-3-(3-diethylaminopropylamino)indazole
  参考文献：
  名称：

  Aminoindazole derivatives

  摘要：

  化合物的式子（I）：##STR1## 其中W.sub.1和W.sub.2各自独立地是氢原子或##STR2##基团，其中Y是n-C.sub.1-6烷基或具有C.sub.1-6烷基取代基的n-C.sub.1-6烷基；R.sub.1和R.sub.2各自独立地是氢原子或C.sub.1-6烷基，并且##STR3##在##STR4##基团中可以形成选择自吗啡啶，吡咯烷，哌啶，同哌啶和哌嗪基团的饱和杂环环，除了吗啡啶基团的饱和杂环环可以具有至少一个C.sub.1-4烷基，羟基或卤素原子作为取代基；Z.sub.1是氢原子，氯原子，溴原子，碘原子，羟基，氨基，C.sub.1-3烷基或甲氧基；Z.sub.2是氢原子或氨基；当W.sub.1和W.sub.2都是氢原子时，Z.sub.1是羟基或碘原子，Z.sub.2是氢原子，或者Z.sub.1和Z.sub.2都是氨基；当Z.sub.1和Z.sub.2都是氢原子时，W.sub.1或W.sub.2中的##STR5##基团是吗啡啶基团；当Z.sub.1是氯原子，羟基，碘原子，甲基或甲氧基时，Z.sub.2是氢原子；当Z.sub.1是氨基时，Z.sub.2是氢原子或氨基；当Z.sub.1是甲基，甲氧基或氨基时，Z.sub.1在5位；当Z.sub.1是碘原子时，Z.sub.1在5-或7-位置；当Z.sub.1和Z.sub.2都是氨基时，Z.sub.1和Z.sub.2在5-和7-位置；以及其生理上可接受的酸加成盐，这些化合物具有药用价值，例如：用于治疗炎症。

  公开号：

  US04533731A1

文献信息

• [EN] PYRIMIDINYL AND 1,3,5 TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY<br/>[FR] PYRIMIDINYL ET 1,3,5-TRIAZINYL BENZIMIDAZOLES ET LEUR UTILISATION EN THÉRAPIE ANTICANCÉREUSE
  申请人：PATHWAY THERAPEUTICS LTD

  公开号：WO2010110686A1

  公开（公告）日：2010-09-30

  Provided herein are pyrimidinyl and 1,3,5-triazinyl benzimidazoles, and their pharmaceutical compositions, preparation, and use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs.

  本文提供了嘧啶基和1,3,5-三嗪基苯并唑类化合物，以及它们的药物组合、制备方法，以及作为抗癌治疗药物或药剂的用途，可以单独使用，也可以与放疗和/或其他抗癌药物联合使用。
• Aminoindazole derivatives
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：US04533731A1

  公开（公告）日：1985-08-06

  A compound of the formula (I): ##STR1## wherein W.sub.1 and W.sub.2 each independently is a hydrogen atom or a ##STR2## group wherein Y is a n-C.sub.1-6 alkylene group or a n-C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.1 and R.sub.2 each independently is a hydrogen atom or a C.sub.1-6 alkyl group, and ##STR3## group in ##STR4## group may form a saturated heterocyclic ring selected from the group consisting of morpholino, pyrrolidino, piperidino, homopiperidino and piperazino groups, and the saturated heterocyclic ring except the morpholino group may have at least one C.sub.1-4 alkyl group, hydroxyl group or halogen atom as a substituent; Z.sub.1 is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxyl group, an amino group, a C.sub.1-3 alkyl group or a methoxy group; Z.sub.2 is a hydrogen atom or an amino group; when W.sub.1 and W.sub.2 are both hydrogen atoms, Z.sub.1 is a hydroxyl group or an iodine atom and Z.sub.2 is hydrogen atom, or Z.sub.1 and Z.sub.2 are both amino groups; when Z.sub.1 and Z.sub.2 are both hydrogen atoms, the ##STR5## group in either W.sub.1 or W.sub.2 is a morpholino group; when Z.sub.1 is a chlorine atom, a hydroxyl group, an iodine atom, a methyl group or a methoxy group, Z.sub.2 is a hydrogen atom; when Z.sub.1 is an amino group, Z.sub.2 is a hydrogen atom or an amino group; when Z.sub.1 is a methyl group, a methoxy group or an amino group, Z.sub.1 is in the 5-position; when Z.sub.1 is an iodine atom, Z.sub.1 is in the 5- or 7-position; and when Z.sub.1 and Z.sub.2 are both amino groups, Z.sub.1 and Z.sub.2 are in the 5- and 7-positions; and the physiologically acceptable acid addition salt thereof which compounds have pharmaceutical utility, e.g.: treating inflammation.

  化合物的式子（I）：##STR1## 其中W.sub.1和W.sub.2各自独立地是氢原子或##STR2##基团，其中Y是n-C.sub.1-6烷基或具有C.sub.1-6烷基取代基的n-C.sub.1-6烷基；R.sub.1和R.sub.2各自独立地是氢原子或C.sub.1-6烷基，并且##STR3##在##STR4##基团中可以形成选择自吗啡啶，吡咯烷，哌啶，同哌啶和哌嗪基团的饱和杂环环，除了吗啡啶基团的饱和杂环环可以具有至少一个C.sub.1-4烷基，羟基或卤素原子作为取代基；Z.sub.1是氢原子，氯原子，溴原子，碘原子，羟基，氨基，C.sub.1-3烷基或甲氧基；Z.sub.2是氢原子或氨基；当W.sub.1和W.sub.2都是氢原子时，Z.sub.1是羟基或碘原子，Z.sub.2是氢原子，或者Z.sub.1和Z.sub.2都是氨基；当Z.sub.1和Z.sub.2都是氢原子时，W.sub.1或W.sub.2中的##STR5##基团是吗啡啶基团；当Z.sub.1是氯原子，羟基，碘原子，甲基或甲氧基时，Z.sub.2是氢原子；当Z.sub.1是氨基时，Z.sub.2是氢原子或氨基；当Z.sub.1是甲基，甲氧基或氨基时，Z.sub.1在5位；当Z.sub.1是碘原子时，Z.sub.1在5-或7-位置；当Z.sub.1和Z.sub.2都是氨基时，Z.sub.1和Z.sub.2在5-和7-位置；以及其生理上可接受的酸加成盐，这些化合物具有药用价值，例如：用于治疗炎症。
• US4533731A
  申请人：——

  公开号：US4533731A

  公开（公告）日：1985-08-06
• US4751302A
  申请人：——

  公开号：US4751302A

  公开（公告）日：1988-06-14
• Indazole derivatives
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：US04751302A1

  公开（公告）日：1988-06-14

  A compound of the formula (I): ##STR1## wherein W.sub.1 and W.sub.2 each independently is a hydrogen atom or a ##STR2## wherein Y is a n-C.sub.1-6 alkylene group or a n-C.sub.1-6 alkylene group having a C.sub.1-6 alkyl group substituent; and R.sub.1 and R.sub.2 each independently is a hydrogen atom or a C.sub.1-6 alkyl group, and ##STR3## may form a saturated heterocyclic ring selected from the group consisting of morpholino, pyrrolidino, piperidino, homopiperidino and piperazino groups, and the saturated heterocyclic ring except the morpholino group may have at least one C.sub.1-4 alkyl group, hydroxyl group or halogen atom as a substituent; Z.sub.1 is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxyl group, an amino group, a C.sub.1-3 alkyl group or a methoxy group; Z.sub.2 is a hydrogen atom or an amino group; when W.sub.1 and W.sub.2 are both hydrogen atoms, Z.sub.1 is a hydroxyl group or an iodine atom and Z.sub.2 is hydrogen atom, or Z.sub.1 and Z.sub.2 are both amino groups; when Z.sub.1 and Z.sub.2 are both hydrogen atoms, the ##STR4## in either W.sub.1 or W.sub.2 is a morpholino group; when Z.sub.1 is a chlorine atom, a hydroxyl group, an iodine atom, a methyl group or a methoxy group, Z.sub.2 is a hydrogen atom; when Z.sub.1 is an amino group, Z.sub.2 is a hydrogen atom or an amino group; when Z.sub.1 is a methyl group, a methoxy group or an amino group, Z.sub.1 is in the 5-position; when Z.sub.1 is an iodine atom, Z.sub.1 is in the 5- or 7-position; and when Z.sub.1 and Z.sub.2 are both amino groups, Z.sub.1 and Z.sub.2 are in the 5- and 7-positions; and the physiologically acceptable acid addition salt thereof.

  化合物的公式（I）：##STR1## 其中W.sub.1和W.sub.2各自独立地是氢原子或##STR2##其中Y是n-C.sub.1-6烷基或具有C.sub.1-6烷基取代基的n-C.sub.1-6烷基；R.sub.1和R.sub.2各自独立地是氢原子或C.sub.1-6烷基，且##STR3##可以形成从吗啡啶，吡咯烷，哌啶，同哌啶和哌嗪基中选出的饱和杂环环，除吗啡啶基外的饱和杂环环可以具有至少一个C.sub.1-4烷基，羟基或卤原子作为取代基；Z.sub.1是氢原子，氯原子，溴原子，碘原子，羟基，氨基，C.sub.1-3烷基或甲氧基；Z.sub.2是氢原子或氨基；当W.sub.1和W.sub.2都是氢原子时，Z.sub.1是羟基或碘原子，Z.sub.2是氢原子，或者Z.sub.1和Z.sub.2都是氨基；当Z.sub.1和Z.sub.2都是氢原子时，W.sub.1或W.sub.2中的##STR4##是吗啡啶基；当Z.sub.1是氯原子，羟基，碘原子，甲基或甲氧基时，Z.sub.2是氢原子；当Z.sub.1是氨基时，Z.sub.2是氢原子或氨基；当Z.sub.1是甲基，甲氧基或氨基时，Z.sub.1在5位；当Z.sub.1是碘原子时，Z.sub.1在5位或7位；当Z.sub.1和Z.sub.2都是氨基时，Z.sub.1和Z.sub.2在5位和7位；以及其生理上可接受的酸加成盐。